NCT06409260 Neuromuscular Monitoring in Children (6 Months - 2 Years) With Electromyography and Acceleromyography
| NCT ID | NCT06409260 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Matias Vested |
| Condition | Neuromuscular Blockade |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2025-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2024-07-01 with a primary completion date of 2025-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to compare AMG and EMG (Philips IntelliVue NMT module and Senzime TetraGraph) in the objective monitoring of neuromuscular blocking in children between the age of 6 months and 2 years.The monitoring will be done bilaterally either on n.ulnaris or n. tibialis. The hypothesis of the study is that AMG will indicate faster recovery time (time to return to TOF 90%) from neuromuscular block than EMG.
Eligibility Criteria
Inclusion Criteria: * Patients 6 months - 2 years of age * Scheduled for elective surgery under general anaesthesia with intubation and use of rocuronium * American Society of Anesthesiologists (ASA) physical status classification I to III Exclusion Criteria: * Known allergy to rocuronium * Neuromuscular disease that may interfere with neuromuscular data * Indication for rapid sequence induction * Prone position
Contact & Investigator
Matias Vested
STUDY CHAIR
Rigshospitalet University of Copenhagen
Frequently Asked Questions
Who can join the NCT06409260 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, up to 2 Years, studying Neuromuscular Blockade. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06409260 currently recruiting?
Yes, NCT06409260 is actively recruiting participants. Contact the research team at matias.vested@regionh.dk for enrollment information.
Where is the NCT06409260 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT06409260 clinical trial?
NCT06409260 is sponsored by Matias Vested. The principal investigator is Matias Vested at Rigshospitalet University of Copenhagen. The trial plans to enroll 120 participants.